MMI270B is a matrix metalloproteinase inhibitor (MMPI) with in vitro and
in vivo activity. To exert optimal target inhibition, MMPI must be given
chronically, and therefore, oral bioavailability is important. We analyzed
the effect of food intake on AUC0-8 h, Cmax, and Tmax. Seventeen patients
were entered into the study. Doses of MMI270B were 150, 400, and 600 mg.
The first day, patients ingested the drug in a fasted state and were not
allowed to eat for 2 h. The second day, patients ingested the drug 30 min
after a light breakfast. Mean AUC0-8 h was not significantly influenced by
food intake. Plasma concentrations were well above the IC50 of several
MMPs at all doses tested. Mean Cmax was significantly decreased after food
intake. Mean Tmax was significantly delayed after food intake. Food intake
did not result in a significant change in exposure to MMI270B (AUC0-8 h)
but did result in a significant, although not clinically relevant,
decrease in peak plasma levels and time to reach peak plasma levels. No
specific guidelines concerning the ingestion of MMI270B in either a fed or
a fasted state are recommended